Concepts (258)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spike Glycoprotein, Coronavirus | 12 | 2025 | 204 | 3.960 |
Why?
|
| Viral Vaccines | 5 | 2021 | 345 | 1.870 |
Why?
|
| Recombinant Proteins | 12 | 2023 | 1433 | 1.820 |
Why?
|
| Lyme Disease | 5 | 2025 | 37 | 1.530 |
Why?
|
| Borrelia burgdorferi | 4 | 2025 | 21 | 1.370 |
Why?
|
| Vaccines, Synthetic | 4 | 2021 | 322 | 1.240 |
Why?
|
| HIV Infections | 14 | 2024 | 2075 | 1.150 |
Why?
|
| Protein Domains | 8 | 2025 | 260 | 1.060 |
Why?
|
| Betacoronavirus | 2 | 2020 | 306 | 1.030 |
Why?
|
| Saccharomycetales | 5 | 2021 | 38 | 1.010 |
Why?
|
| South Africa | 20 | 2024 | 127 | 0.980 |
Why?
|
| Ixodes | 2 | 2022 | 18 | 0.960 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2025 | 30 | 0.940 |
Why?
|
| Coronavirus Infections | 3 | 2021 | 385 | 0.940 |
Why?
|
| Middle East Respiratory Syndrome Coronavirus | 1 | 2025 | 23 | 0.930 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 395 | 0.900 |
Why?
|
| Vaccines, Subunit | 2 | 2024 | 70 | 0.880 |
Why?
|
| Pandemics | 3 | 2021 | 1193 | 0.870 |
Why?
|
| Breast Neoplasms | 11 | 2025 | 2771 | 0.870 |
Why?
|
| Sarcoma, Kaposi | 5 | 2023 | 137 | 0.860 |
Why?
|
| Protozoan Proteins | 2 | 2022 | 135 | 0.840 |
Why?
|
| Phlebotomus | 2 | 2020 | 17 | 0.820 |
Why?
|
| Leishmaniasis Vaccines | 2 | 2020 | 20 | 0.820 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2024 | 865 | 0.800 |
Why?
|
| Gene Expression | 4 | 2021 | 1611 | 0.750 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2025 | 805 | 0.750 |
Why?
|
| Trypanosoma cruzi | 2 | 2022 | 251 | 0.740 |
Why?
|
| Pichia | 2 | 2017 | 56 | 0.640 |
Why?
|
| Viral Envelope Proteins | 1 | 2020 | 155 | 0.620 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2024 | 266 | 0.620 |
Why?
|
| Chagas Disease | 2 | 2022 | 309 | 0.610 |
Why?
|
| Esophageal Neoplasms | 1 | 2023 | 389 | 0.600 |
Why?
|
| DNA | 2 | 2018 | 1683 | 0.600 |
Why?
|
| Chromatography, Ion Exchange | 4 | 2014 | 67 | 0.590 |
Why?
|
| Papillomavirus Infections | 4 | 2024 | 401 | 0.580 |
Why?
|
| Saccharomyces cerevisiae | 6 | 2023 | 440 | 0.570 |
Why?
|
| Blood Preservation | 1 | 2018 | 32 | 0.560 |
Why?
|
| Cryopreservation | 1 | 2018 | 76 | 0.550 |
Why?
|
| Blood | 1 | 2018 | 108 | 0.550 |
Why?
|
| Lyme Disease Vaccines | 4 | 2025 | 12 | 0.530 |
Why?
|
| Mice, Inbred BALB C | 6 | 2024 | 1083 | 0.510 |
Why?
|
| Antibodies, Viral | 7 | 2024 | 1205 | 0.510 |
Why?
|
| Neoplasms | 5 | 2024 | 3035 | 0.460 |
Why?
|
| Prostatic Neoplasms | 4 | 2024 | 1626 | 0.420 |
Why?
|
| Animals | 20 | 2025 | 36222 | 0.410 |
Why?
|
| Oncogene Proteins, Viral | 2 | 2024 | 66 | 0.400 |
Why?
|
| Herpesvirus 8, Human | 2 | 2023 | 52 | 0.380 |
Why?
|
| Humans | 51 | 2025 | 133811 | 0.380 |
Why?
|
| Genome, Human | 1 | 2018 | 1350 | 0.340 |
Why?
|
| Alum Compounds | 3 | 2022 | 42 | 0.340 |
Why?
|
| Salivary Proteins and Peptides | 2 | 2020 | 19 | 0.340 |
Why?
|
| Insect Proteins | 2 | 2020 | 111 | 0.320 |
Why?
|
| Cloning, Molecular | 3 | 2021 | 911 | 0.320 |
Why?
|
| Protozoan Vaccines | 2 | 2022 | 96 | 0.320 |
Why?
|
| Antibodies, Neutralizing | 6 | 2024 | 498 | 0.310 |
Why?
|
| Mice | 11 | 2025 | 18936 | 0.310 |
Why?
|
| Severe Acute Respiratory Syndrome | 2 | 2020 | 37 | 0.300 |
Why?
|
| Case-Control Studies | 7 | 2024 | 3644 | 0.300 |
Why?
|
| Adjuvants, Immunologic | 3 | 2024 | 391 | 0.300 |
Why?
|
| Complement Factor H | 3 | 2025 | 24 | 0.270 |
Why?
|
| Female | 30 | 2025 | 71840 | 0.270 |
Why?
|
| Bacterial Proteins | 2 | 2025 | 924 | 0.270 |
Why?
|
| RNA | 1 | 2010 | 606 | 0.260 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2025 | 457 | 0.260 |
Why?
|
| Prostate-Specific Antigen | 2 | 2023 | 275 | 0.240 |
Why?
|
| Cricetulus | 1 | 2025 | 97 | 0.230 |
Why?
|
| CHO Cells | 1 | 2025 | 167 | 0.230 |
Why?
|
| Tobacco, Smokeless | 1 | 2024 | 14 | 0.230 |
Why?
|
| Viral Load | 3 | 2022 | 411 | 0.230 |
Why?
|
| Epitopes | 2 | 2022 | 444 | 0.210 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2024 | 114 | 0.210 |
Why?
|
| Leukopenia | 1 | 2023 | 48 | 0.210 |
Why?
|
| Africa South of the Sahara | 4 | 2025 | 129 | 0.200 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2023 | 35 | 0.200 |
Why?
|
| Androgen Antagonists | 1 | 2023 | 136 | 0.200 |
Why?
|
| Vaccines, Combined | 1 | 2022 | 39 | 0.200 |
Why?
|
| Borrelia burgdorferi Group | 1 | 2022 | 5 | 0.200 |
Why?
|
| Antiparasitic Agents | 1 | 2022 | 31 | 0.200 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2022 | 453 | 0.190 |
Why?
|
| Interleukin-4 | 1 | 2022 | 148 | 0.190 |
Why?
|
| Antibodies, Protozoan | 1 | 2022 | 95 | 0.190 |
Why?
|
| HIV Seropositivity | 1 | 2023 | 128 | 0.190 |
Why?
|
| Spectrometry, Fluorescence | 2 | 2012 | 87 | 0.180 |
Why?
|
| Obesity, Abdominal | 1 | 2021 | 41 | 0.180 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2024 | 277 | 0.180 |
Why?
|
| Middle Aged | 12 | 2025 | 29287 | 0.180 |
Why?
|
| Fermentation | 2 | 2020 | 71 | 0.180 |
Why?
|
| Borrelia | 1 | 2022 | 82 | 0.170 |
Why?
|
| Aluminum Hydroxide | 1 | 2020 | 39 | 0.170 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 238 | 0.170 |
Why?
|
| Mastectomy | 1 | 2020 | 82 | 0.170 |
Why?
|
| Leishmania | 1 | 2020 | 35 | 0.170 |
Why?
|
| Adsorption | 4 | 2014 | 37 | 0.170 |
Why?
|
| Ticks | 1 | 2020 | 33 | 0.160 |
Why?
|
| Pepsin A | 1 | 2019 | 12 | 0.160 |
Why?
|
| Aspartic Acid Proteases | 1 | 2019 | 9 | 0.160 |
Why?
|
| Africa | 1 | 2020 | 141 | 0.160 |
Why?
|
| Mammography | 1 | 2020 | 133 | 0.160 |
Why?
|
| Neoplasm Staging | 1 | 2023 | 1383 | 0.160 |
Why?
|
| Protein Subunits | 1 | 2020 | 174 | 0.160 |
Why?
|
| Cytokines | 2 | 2022 | 1381 | 0.160 |
Why?
|
| Seroepidemiologic Studies | 3 | 2024 | 144 | 0.150 |
Why?
|
| HIV-1 | 1 | 2023 | 489 | 0.150 |
Why?
|
| Alcoholism | 1 | 2021 | 253 | 0.150 |
Why?
|
| Protein Structure, Tertiary | 1 | 2021 | 787 | 0.150 |
Why?
|
| Ultraviolet Rays | 1 | 2019 | 211 | 0.150 |
Why?
|
| Amino Acid Sequence | 2 | 2021 | 2785 | 0.150 |
Why?
|
| Time Factors | 2 | 2020 | 6554 | 0.150 |
Why?
|
| Adult | 10 | 2025 | 31823 | 0.150 |
Why?
|
| Quality Indicators, Health Care | 1 | 2020 | 231 | 0.140 |
Why?
|
| Data Collection | 1 | 2020 | 399 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2024 | 3506 | 0.140 |
Why?
|
| Industrial Microbiology | 1 | 2017 | 7 | 0.140 |
Why?
|
| Antigens, Protozoan | 1 | 2017 | 80 | 0.140 |
Why?
|
| Proteins | 2 | 2014 | 1099 | 0.140 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2023 | 402 | 0.140 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 416 | 0.130 |
Why?
|
| Calcium-Binding Proteins | 1 | 2017 | 334 | 0.130 |
Why?
|
| Smoking | 1 | 2021 | 1134 | 0.120 |
Why?
|
| Prospective Studies | 5 | 2025 | 6602 | 0.120 |
Why?
|
| Genome-Wide Association Study | 1 | 2023 | 1880 | 0.120 |
Why?
|
| Male | 13 | 2024 | 65939 | 0.120 |
Why?
|
| Neoadjuvant Therapy | 3 | 2023 | 407 | 0.120 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 643 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 938 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2023 | 2948 | 0.110 |
Why?
|
| Stochastic Processes | 1 | 2014 | 38 | 0.110 |
Why?
|
| Spermine | 1 | 2013 | 5 | 0.110 |
Why?
|
| Sepharose | 1 | 2013 | 14 | 0.110 |
Why?
|
| Levivirus | 1 | 2013 | 3 | 0.110 |
Why?
|
| Hypertension | 1 | 2023 | 1403 | 0.110 |
Why?
|
| Encephalitis Virus, Japanese | 1 | 2013 | 22 | 0.110 |
Why?
|
| Glycosylation | 1 | 2013 | 128 | 0.110 |
Why?
|
| Aged | 7 | 2025 | 21714 | 0.100 |
Why?
|
| Human papillomavirus 18 | 2 | 2024 | 14 | 0.100 |
Why?
|
| Administration, Intranasal | 2 | 2024 | 138 | 0.100 |
Why?
|
| Aptamers, Nucleotide | 1 | 2013 | 37 | 0.100 |
Why?
|
| Multimorbidity | 2 | 2023 | 26 | 0.100 |
Why?
|
| Human papillomavirus 16 | 2 | 2024 | 99 | 0.100 |
Why?
|
| Risk Factors | 3 | 2024 | 11166 | 0.100 |
Why?
|
| Papillomaviridae | 2 | 2024 | 191 | 0.090 |
Why?
|
| Cohort Studies | 4 | 2022 | 5219 | 0.090 |
Why?
|
| Prevalence | 3 | 2024 | 2639 | 0.090 |
Why?
|
| Tamoxifen | 2 | 2023 | 377 | 0.090 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2023 | 271 | 0.090 |
Why?
|
| Anti-Retroviral Agents | 2 | 2023 | 154 | 0.090 |
Why?
|
| Salmon | 1 | 2010 | 5 | 0.090 |
Why?
|
| Osmolar Concentration | 1 | 2010 | 177 | 0.090 |
Why?
|
| Sodium Chloride | 1 | 2010 | 99 | 0.080 |
Why?
|
| Nanoparticles | 1 | 2013 | 289 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2013 | 444 | 0.080 |
Why?
|
| Antibodies | 2 | 2022 | 372 | 0.080 |
Why?
|
| Polyethylene Glycols | 1 | 2011 | 254 | 0.080 |
Why?
|
| Incidence | 3 | 2022 | 3416 | 0.080 |
Why?
|
| Protein Stability | 2 | 2020 | 175 | 0.080 |
Why?
|
| Life Style | 2 | 2022 | 463 | 0.070 |
Why?
|
| Peptides | 1 | 2012 | 863 | 0.070 |
Why?
|
| Binding Sites | 2 | 2022 | 1379 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2022 | 1488 | 0.070 |
Why?
|
| Models, Molecular | 2 | 2025 | 1147 | 0.060 |
Why?
|
| Freeze Drying | 1 | 2024 | 16 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 1358 | 0.060 |
Why?
|
| Injections, Intramuscular | 1 | 2024 | 198 | 0.060 |
Why?
|
| Lactalbumin | 2 | 2014 | 11 | 0.050 |
Why?
|
| Vaginal Neoplasms | 1 | 2024 | 19 | 0.050 |
Why?
|
| Vulvar Neoplasms | 1 | 2024 | 23 | 0.050 |
Why?
|
| Penile Neoplasms | 1 | 2024 | 36 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 3739 | 0.050 |
Why?
|
| Crystallography, X-Ray | 1 | 2025 | 393 | 0.050 |
Why?
|
| Vaginal Smears | 1 | 2024 | 55 | 0.050 |
Why?
|
| Filgrastim | 1 | 2023 | 13 | 0.050 |
Why?
|
| Anus Neoplasms | 1 | 2024 | 42 | 0.050 |
Why?
|
| Neoplasm Grading | 1 | 2024 | 307 | 0.050 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2024 | 116 | 0.050 |
Why?
|
| Protein Binding | 2 | 2021 | 1853 | 0.050 |
Why?
|
| Antigens, Bacterial | 1 | 2025 | 312 | 0.050 |
Why?
|
| Antibodies, Bacterial | 1 | 2025 | 401 | 0.050 |
Why?
|
| Gene Frequency | 1 | 2024 | 780 | 0.050 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2022 | 23 | 0.050 |
Why?
|
| Zimbabwe | 1 | 2022 | 11 | 0.050 |
Why?
|
| Technology | 1 | 2023 | 70 | 0.050 |
Why?
|
| Contraceptive Agents | 1 | 2022 | 15 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2024 | 635 | 0.050 |
Why?
|
| Lipoproteins, HDL | 1 | 2022 | 118 | 0.050 |
Why?
|
| Cattle | 2 | 2013 | 588 | 0.050 |
Why?
|
| Developing Countries | 1 | 2024 | 290 | 0.050 |
Why?
|
| Waist-Hip Ratio | 1 | 2021 | 60 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2022 | 129 | 0.050 |
Why?
|
| Parity | 1 | 2021 | 89 | 0.050 |
Why?
|
| HIV | 1 | 2023 | 193 | 0.050 |
Why?
|
| Waist Circumference | 1 | 2021 | 95 | 0.050 |
Why?
|
| Hospitals, Teaching | 1 | 2021 | 115 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2024 | 510 | 0.040 |
Why?
|
| Administration, Inhalation | 1 | 2021 | 186 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2023 | 1145 | 0.040 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2024 | 286 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2021 | 299 | 0.040 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2020 | 48 | 0.040 |
Why?
|
| Obesity | 2 | 2023 | 2445 | 0.040 |
Why?
|
| Molecular Weight | 1 | 2020 | 384 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2022 | 842 | 0.040 |
Why?
|
| Mice, Inbred C3H | 1 | 2020 | 122 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2022 | 337 | 0.040 |
Why?
|
| Complement System Proteins | 1 | 2020 | 58 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2021 | 325 | 0.040 |
Why?
|
| Age Distribution | 1 | 2021 | 434 | 0.040 |
Why?
|
| Macaca mulatta | 1 | 2021 | 513 | 0.040 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2019 | 49 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2024 | 1491 | 0.040 |
Why?
|
| Cholesterol | 1 | 2022 | 574 | 0.040 |
Why?
|
| Health Resources | 1 | 2021 | 127 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2023 | 897 | 0.040 |
Why?
|
| Mortality | 1 | 2021 | 261 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2020 | 242 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2021 | 824 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2024 | 873 | 0.040 |
Why?
|
| Young Adult | 2 | 2025 | 9926 | 0.040 |
Why?
|
| Pregnancy | 2 | 2022 | 7599 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2025 | 1049 | 0.040 |
Why?
|
| Protein Folding | 1 | 2019 | 222 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 1234 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 791 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2021 | 509 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2024 | 1031 | 0.040 |
Why?
|
| Freezing | 1 | 2017 | 29 | 0.040 |
Why?
|
| Glucose | 1 | 2022 | 917 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2024 | 1104 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2019 | 873 | 0.030 |
Why?
|
| Genetic Variation | 1 | 2024 | 1630 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2024 | 1146 | 0.030 |
Why?
|
| Temperature | 1 | 2017 | 326 | 0.030 |
Why?
|
| Consensus | 1 | 2020 | 725 | 0.030 |
Why?
|
| Genotype | 1 | 2023 | 2819 | 0.030 |
Why?
|
| Logistic Models | 1 | 2021 | 1902 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2020 | 966 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2025 | 5455 | 0.030 |
Why?
|
| Cell Line | 1 | 2021 | 2861 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1160 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2021 | 1722 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2020 | 701 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 3047 | 0.030 |
Why?
|
| RNA, Fungal | 1 | 2013 | 15 | 0.030 |
Why?
|
| Horseradish Peroxidase | 1 | 2013 | 14 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2014 | 77 | 0.030 |
Why?
|
| Registries | 1 | 2021 | 1586 | 0.030 |
Why?
|
| Lung | 1 | 2021 | 1573 | 0.030 |
Why?
|
| Serum Albumin, Bovine | 1 | 2013 | 56 | 0.030 |
Why?
|
| Muramidase | 1 | 2013 | 99 | 0.030 |
Why?
|
| Chickens | 1 | 2013 | 639 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 1770 | 0.020 |
Why?
|
| Ligands | 1 | 2013 | 571 | 0.020 |
Why?
|
| Kinetics | 1 | 2014 | 1323 | 0.020 |
Why?
|
| Surface Properties | 1 | 2011 | 96 | 0.020 |
Why?
|
| Protein Transport | 1 | 2012 | 390 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 3966 | 0.020 |
Why?
|
| United States | 1 | 2021 | 11760 | 0.010 |
Why?
|
| Adolescent | 1 | 2021 | 20610 | 0.010 |
Why?
|
| Child | 1 | 2022 | 25882 | 0.010 |
Why?
|